| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 8772 | 2012 |
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ... Journal of clinical oncology 29 (17), 2357, 2011 | 351 | 2011 |
| Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) R Dhanasekaran, DA Kooby, CA Staley, JS Kauh, V Khanna, HS Kim Journal of surgical oncology 101 (6), 476-480, 2010 | 279 | 2010 |
| A phase I trial of depsipeptide (FR901228) in patients with advanced cancer JL Marshall, N Rizvi, J Kauh, W Dahut, M Figuera, MH Kang, WD Figg, ... Journal of Experimental Therapeutics and Oncology 2 (6), 325-332, 2002 | 256 | 2002 |
| Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma H Mahaseth, E Brutcher, J Kauh, N Hawk, S Kim, Z Chen, DA Kooby, ... Pancreas 42 (8), 1311-1315, 2013 | 232 | 2013 |
| Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma DA Kooby, V Egnatashvili, S Srinivasan, A Chamsuddin, KA Delman, ... Journal of vascular and interventional radiology 21 (2), 224-230, 2010 | 218 | 2010 |
| Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma BH O'Neil, LW Goff, JSW Kauh, JR Strosberg, TS Bekaii-Saab, R Lee, ... Journal of Clinical Oncology 29 (17), 2350, 2011 | 173 | 2011 |
| Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors J Sarantopoulos, GI Shapiro, RB Cohen, JW Clark, JS Kauh, GJ Weiss, ... Clinical Cancer Research 22 (4), 847-857, 2016 | 167 | 2016 |
| Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study S Rafi, SM Piduru, B El-Rayes, JS Kauh, DA Kooby, JM Sarmiento, ... Cardiovascular and interventional radiology 36, 440-448, 2013 | 149 | 2013 |
| mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by … HJ Prajapati, JR Spivey, SI Hanish, BF El-Rayes, JS Kauh, Z Chen, ... Annals of oncology 24 (4), 965-973, 2013 | 147 | 2013 |
| Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues S Fan, SS Ramalingam, J Kauh, Z Xu, FR Khuri, SY Sun Cancer biology & therapy 8 (15), 1463-1469, 2009 | 145 | 2009 |
| Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group’s Study E1203 PJ O’Dwyer, BJ Giantonio, DE Levy, JS Kauh, DB Fitzgerald, ... Journal of Clinical Oncology 24 (18_suppl), 4143-4143, 2006 | 143 | 2006 |
| Examining racial disparities in colorectal cancer care J Berry, K Bumpers, V Ogunlade, R Glover, S Davis, M Counts-Spriggs, ... Journal of psychosocial oncology 27 (1), 59-83, 2009 | 112 | 2009 |
| Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer A phase 1 trial AJ Ocean, KL Pennington, MJ Guarino, A Sheikh, T Bekaii‐Saab, ... Cancer 118 (22), 5497-5506, 2012 | 103 | 2012 |
| Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy X Wang, N Hawk, P Yue, J Kauh, SS Ramalingam, H Fu, FR Khuri, ... Cancer biology & therapy 7 (12), 1952-1958, 2008 | 102 | 2008 |
| A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors AW Tolcher, JD Berlin, J Cosaert, J Kauh, E Chan, SA Piha-Paul, ... Cancer chemotherapy and pharmacology 79, 673-680, 2017 | 94 | 2017 |
| Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC HJ Prajapati, M Xing, JR Spivey, SI Hanish, BF El-Rayes, JS Kauh, ... American Journal of Roentgenology 203 (6), W706-W714, 2014 | 87 | 2014 |
| Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma HJ Prajapati, R Dhanasekaran, BF El-Rayes, JS Kauh, SK Maithel, ... Journal of Vascular and Interventional Radiology 24 (3), 307-315, 2013 | 86 | 2013 |
| Gastric cancer: standards for the 21st century V Archie, J Kauh, DV Jones Jr, V Cruz, MS Karpeh Jr, CR Thomas Jr Critical reviews in oncology/hematology 57 (2), 123-131, 2006 | 83 | 2006 |
| Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm … DP Petrylak, ST Tagawa, M Kohli, A Eisen, C Canil, SS Sridhar, A Spira, ... J Clin Oncol 34 (13), 1500-1509, 2016 | 82 | 2016 |
